نتایج جستجو برای: bone loss

تعداد نتایج: 727243  

2010
Iwen F Grigsby Lan Pham Louis M Mansky Raj Gopalakrishnan Kim C Mansky

Clinical observations have revealed a strong correlation between loss of bone density in HIV-infected individuals, particularly in conjunction with the antiretroviral drug tenofovir, a nucleotide analog that inhibits HIV reverse transcriptase. The most compelling correlations have been observed in clinical studies involving young children and adolescents. These observations strongly suggest tha...

Journal: :Oncology 2006
Edith A Perez Katherine Weilbaecher

The aromatase inhibitors (AIs) anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are significantly more effective than the selective estrogen-receptor modulator (SERM) tamoxifen in preventing recurrence in estrogen receptor-positive early breast cancer. Aromatase inhibitors are likely to replace SERMs as first-line adjuvant therapy for many patients. However, AIs are associa...

Journal: :Oncology nursing forum 2011
Jane Bryce Martina Bauer Peyman Hadji

273 A 49-year-old postmenopausal Caucasian woman named M.A. was diagnosed with estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2-negative breast cancer. Anthracycline and taxane-based adjuvant chemotherapy and radiation therapy were followed by adjuvant therapy with an aromatase inhibitor (AI). Before M.A. started adjuvant AI therapy, she was evaluated for any additiona...

پایان نامه :وزارت بهداشت، درمان و آموزش پزشکی - دانشگاه علوم پزشکی و خدمات بهداشتی درمانی مشهد - دانشکده دندانپزشکی 1391

مقدمه و هدف : یکی از عوامل مهم و تاثیرگذارجهت دستیابی به انطباق بدون تنش در پروتزهای متکی بر ایمپلنت، انجام قالبگیری دقیق می باشد. دو روش قالبگیری مستقیم و غیرمستقیم برای انتقال موقعیت ایمپلنت از دهان به کست کار وجود دارد. هدف از انجام این مطالعه بررسی دقت وسایل رایج جهت قالبگیری به روش غیرمستقیم درسه نوع سیستم مختلف ایمپلنت دندانی و مقایسه آنها با روش مستقیم می باشد. مواد و روش ها : در...

2017

The aromatase inhibitors (AIs) anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are significantly more effective than the selective estrogen-receptor modulator (SERM) tamoxifen in preventing recurrence in estrogen receptor-positive early breast cancer. Aromatase inhibitors are likely to replace SERMs as first-line adjuvant therapy for many patients. However, AIs are associa...

Journal: :dental research journal 0
anushi mahajan suresh kedige

background: bone loss is one of the hallmarks of periodontitis. hence, a major focus of research into periodontal regeneration has concentrated on the initiation of osteogenesis. osteoinduction requires the differentiation of mesenchymal cells into osteoblasts with subsequent formation of new bone. the present study has been carried out to evaluate periodontal bone regeneration in intrabony def...

Journal: :acta medica iranica 0
m. h. baradaranfar p. dabirmoghaddam

otosclerosis is the most frequent cause of conductive hearing loss in patients with intact tympanic membrane. it can be treated by surgery with various techniques. because of limited manipulation and comparably similar results, stapedotomy at present is preferred over other surgical techniques by most surgeons. here we present the operative results of 114 otosclerotic patients who underwent sta...

Journal: :Clinical and experimental rheumatology 2000
B Cortet M H Guyot E Solau P Pigny F Dumoulin R M Flipo X Marchandise B Delcambre

OBJECTIVES To assess the occurrence of bone loss in rheumatoid arthritis (RA) and to determine the factors influencing bone loss (particularly the usefulness of bone turnover markers) over an 18-month period. METHODS A total of 51 patients were studied, 6 men and 45 females (of whom 35 were menopausal). Their mean age was 56 +/- 10 years and the mean RA duration was 12 +/- 10 years. Twenty-ei...

Journal: :Obstetrical & gynecological survey 2006
James A Simon Lois E Wehren Brynne H Ascott-Evans Molly K N Omizo Sheryl L Silfen Antonio Lombardi

UNLABELLED Although hormone therapy protects against bone loss after menopause, currently it is not recommended once menopausal symptoms have subsided. We reviewed randomized clinical trials to quantify bone loss after stopping hormone therapy and summarize treatment options for women who discontinue hormone treatment. We conducted a search of MEDLINE and EMBASE for randomized, controlled trial...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید